Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Ipamorelin, the first selective growth hormone secretagogue

Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. European Journal of Endocrinology 1998

Document identifier
CEI-BR-091
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH
Title
Ipamorelin, the first selective growth hormone secretagogue
Source
European Journal of Endocrinology
Year
1998
Volume, issue, pages
139(5):552–561
Digital object identifier
10.1530/eje.0.1390552
PubMed identifier
9849822
Record type
Journal article
Institute identifier
CEI-BR-091

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: IpamorelinCompound monograph
Monograph: HexarelinCompound monograph
Monograph: GHRP-2Compound monograph
Monograph: GHRP-6Compound monograph
4 citing documents.

§1.3Subject tags

ipamorelin preclinical ghs

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.